Brief cognitive-based psychosocial intervention and case management for suicide attempters discharged from the emergency department in Taipei, Taiwan: a randomized controlled study - Lin YC, Liu SI, Chen SC, Sun FJ, Huang HC, Huang CR, Chiu YC.
We examined the effectiveness of brief cognitive-based psychotherapy plus standard case management in the prevention of further suicide attempts, clinical severity, and treatment adherence in a randomized clinical trial compared with standard ca... (Source: SafetyLit)
Source: SafetyLit - February 21, 2020 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news

Startup gobbles up $60M from high-profile investors to target food allergies
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 21, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Startup gobbles up $60M from high-profile investors to target food allergies
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 21, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Suicidal Patients Often Excluded From Antidepressant Trials Suicidal Patients Often Excluded From Antidepressant Trials
Clinical trials of antidepressants that inform FDA approval decisions often exclude suicidal patients, leaving clinicians uncertain of the efficacy of these drugs in this patient population.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 21, 2020 Category: Neurology Tags: Psychiatry News Source Type: news

Clinical trials of intravenous vitamin C treatments for coronavirus commence in China
(Natural News) Researchers in China have begun clinical trials on the use of intravenous vitamin C as a remedy for the Wuhan coronavirus (CoVid-19). While government health authorities focus on pharmaceuticals and vaccines, Dr. Richard Cheng and his colleagues are investigating the simplicity with which injecting natural vitamin C can help to prevent the deadly... (Source: NaturalNews.com)
Source: NaturalNews.com - February 21, 2020 Category: Consumer Health News Source Type: news

China says earliest coronavirus vaccine to be submitted for trials late April
The earliest vaccine for the coronavius that has killed more than 2,000 in China alone will be submitted for clinical trials around late April, China's Vice Science and Technology Minister Xu Nanping said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - February 21, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Startup gobbles up $60M from high-profile investors to target food allergies
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 20, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Startup gobbles up $60M from high-profile investors to target food allergies
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 20, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

How Artificial Intelligence Can Help Pick the Best Depression Treatments for You
Seeking out help for depression is hard enough. It doesn’t make things any easier that it can take weeks, months or longer of trying different treatments to find something that works. Doctors typically start patients on antidepressants, but they take at least four weeks to start working, and research has shown that only about 30% respond well to the first drug they’re prescribed. “Right now, treatment selection is purely based on trial and error,” says Dr. Madhukar Trivedi, a professor of psychiatry at the University of Texas Southwestern Medical Center. But promising new research published in Febru...
Source: TIME: Health - February 20, 2020 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized Artificial Intelligence medicine mental health onetime psychiatry Source Type: news

Effect of Incisional Negative Pressure Wound Therapy vs Standard Wound Dressing on Deep Surgical Site Infection After Surgery for Lower Limb Fractures Associated With Major Trauma The WHIST Randomized Clinical Trial
The findings of this study do not support the use of incisional negative pressure wound therapy for surgical wounds associated with lower limb fractures from major trauma, although the event rate at 30 days was lower than expected. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 20, 2020 Category: Consumer Health News Source Type: news

Research shows new drug helps to preserve brain cells for a time after stroke
After 50 years of research and the testing of over 1,000 drugs, there is new hope for preserving brain cells for a time after stroke. Treating acute ischemic stroke patients with an experimental neuroprotective drug, combined with a surgical procedure to remove the clot improves outcomes as shown by clinical trial results published today in The Lancet. (Source: World Pharma News)
Source: World Pharma News - February 20, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Research shows new drug helps to preserve brain cells for a time after stroke
(University of Calgary) After 50 years of research and the testing of over 1,000 drugs, there is new hope for preserving brain cells for a time after stroke. Treating acute ischemic stroke patients with an experimental neuroprotective drug, combined with a surgical procedure to remove the clot improves outcomes as shown by clinical trial results published today in The Lancet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2020 Category: International Medicine & Public Health Source Type: news

Hispanics/Latinos underrepresented in Alzheimer's disease research
(University of Houston) The largest ethnic minority in the US, at 18% of the population, Hispanics/Latinos are 50% more likely to develop Alzheimer's disease than non-Hispanic whites, yet they comprise less than 1% of clinical trials for Alzheimer's. A University of Houston researcher is set on changing that, by increasing health literacy among Hispanics/Latinos and closing the health disparity gap. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 20, 2020 Category: International Medicine & Public Health Source Type: news

Clinical trial exposes deadly kidney cancer's Achilles' heel
(UT Southwestern Medical Center) An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

New study supports the safety of varenicline
(Society for the Study of Addiction) A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT). These findings confirm those of earlier clinical trials, providing further evidence of the safety of varenicline as an aid to stop smoking. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 20, 2020 Category: International Medicine & Public Health Source Type: news

Assessing the Competition in Rare Disease Clinical Trials: The Need...
This webinar will provide an in-depth perspective from the experts developing the most innovative feasibility strategies being applied to the rare diseases of today.(PRWeb February 20, 2020)Read the full story at https://www.prweb.com/releases/assessing_the_competition_in_rare_disease_clinical_trials_the_need_for_a_thorough_feasibility_strategy_upcoming_webinar_hosted_by_xtalks/prweb16922730.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 20, 2020 Category: Pharmaceuticals Source Type: news

Upstate clinical trial seeks to examine whether nicotine in patch form can improve long term memory and functioning
Study seeks healthy, non-smoking adults, age 55+ who have noticed changes in their memory or whose family members have noticed changes. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 19, 2020 Category: Universities & Medical Training Tags: News Source Type: news

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial TOKYO and BOTHELL, Wash., Feb. 19, 2020 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.... Biopharmaceuticals, Oncology, FDA Astellas Pharma, Seattle Genetics, Enfortumab Vedotin, Urothelial Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus vaccine could be available 'within months', claims Oxford University scientist
Professor Sarah Gilbert is working to develop a vaccine at the Jenner Institute at Oxford University. An initial 1,000 doses will soon be made in Italy for clinical trials. (Source: the Mail online | Health)
Source: the Mail online | Health - February 19, 2020 Category: Consumer Health News Source Type: news

Bioelectronic Research Tackles Hemorrhagic Shock
Jared Huston, MD, a trauma surgeon at Northwell Health on New York's Long Island, spoke straight to the point about the current state of treatment for hemorrhagic shock. While traumatic wounds to extremities can be treated with a tourniquet, such wounds suffered internally are often fatal unless the patient can be transported quickly to an operating room. "There are no efficacious approaches to treating noncompressible hemorrhage," Huston said. "That's really the problem. If you're injured intra-abdominally or in the chest, and you're not brought somewhere where a trauma surgeon can operate on you and stop t...
Source: MDDI - February 19, 2020 Category: Medical Devices Authors: Greg Goth Tags: Electronics Source Type: news

Clinicians in the dark about potential harms of commonly prescribed beta blocker
Better understanding needed to stave off overdose deaths, warns HSIB Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Too few women take part in many CVD clinical trials Pharmacists could offer high-dose statins direct to patients Cannabinoids not recommended to treat cancer-related pain GPs defend practice on prescribing statins (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 19, 2020 Category: UK Health Source Type: news

Women Patients Still Missing in Heart Research
Women accounted for less than 40% of all people enrolled in cardiovascular clinical trials from 2010 through 2017, according to a study published Feb. 17 in the journal Circulation. (Source: WebMD Health)
Source: WebMD Health - February 18, 2020 Category: Consumer Health News Source Type: news

Sanofi teams up with U.S. agency against coronavirus
French drugmaker Sanofi is working with a U.S. government agency to develop a vaccine against the new coronavirus from China, saying it could have a candidate ready for clinical trials within a year. (Source: Reuters: Health)
Source: Reuters: Health - February 18, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Grail Hits Another Milestone by Initiating PATHFINDER Study
Grail is making some headway in its mission to develop a liquid biopsy solution to detect cancer early. The Menlo Park, CA-based company said it has initiated PATHFINDER, a multi-center study. PATHFINDER will mark the first time Grail’s test results will be returned to healthcare providers and communicated to participants to help guide appropriate diagnostic workups for more than 50 cancer types. “Grail is at the forefront of transforming early cancer detection as we bring our multi-cancer test into clinical practice through our first interventional study,” Hans Bishop,...
Source: MDDI - February 18, 2020 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

' Incredible' Results With Kidney Cancer Agent With Nobel Ties'Incredible' Results With Kidney Cancer Agent With Nobel Ties
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases
New therapeutic approaches for chronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis are needed because current treatments are often suboptimal in terms of both efficacy and the risks of serious adverse events. Inhibitor of apoptosis proteins (IAPs) are E3 ubiquitin ligases that inhibit cell death pathways and are themselves inhibited by second mitochondria-derived activator of caspases (SMAC). SMAC mimetics (SMs), small-molecule antagonists of IAPs, are being evaluated as cancer therapies in clinical trials. IAPs are also crucial regulators of inflammatory pathways because t...
Source: Signal Transduction Knowledge Environment - February 18, 2020 Category: Science Authors: Jensen, S., Seidelin, J. B., LaCasse, E. C., Nielsen, O. H. Tags: STKE Reviews Source Type: news

Mesothelioma Gene Therapy Trial Shows ‘Real Potential’
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - February 17, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gene Therapy for Mesothelioma Has ‘Real Potential’
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - February 17, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Neuro-ophthalmologic response to repetitive subconcussive head impacts: a randomized clinical trial - Nowak MK, Bevilacqua ZW, Ejima K, Huibregtse ME, Chen Z, Mickleborough TD, Newman SD, Kawata K.
IMPORTANCE: Subconcussive head impacts have emerged as a complex public health concern. The oculomotor system is sensitive to brain trauma; however, neuro-ophthalmologic response to subconcussive head impacts remains unclear. OBJECTIVE: To examine ... (Source: SafetyLit)
Source: SafetyLit - February 17, 2020 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news

World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate, and severe alcohol dependence in clinical trials in the United States and United Kingdom - Witkiewitz K, Heather N, Falk DE, Litten RZ, Hasin DS, Kranzler HR, Mann KF, O'Malley SS, Anton RF.
AIMS: To examine whether World Health Organization (WHO) risk level reductions in drinking were achievable, associated with improved functioning, and maintained over time among patients at varying initial alcohol dependence severity levels. DESIGN AND SETT... (Source: SafetyLit)
Source: SafetyLit - February 17, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

A Failed Strategy for an Effective Bladder Cancer Drug A Failed Strategy for an Effective Bladder Cancer Drug
When the number of doses of BCG for high-grade non-muscle invasive bladder cancer was cut, outcomes were inferior in a randomized clinical trial.Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - February 17, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells
The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Andrew J. Cowan, MD Source Type: news

Test measures immune response to improve ovarian cancer diagnosis
(RMIT University) About 300,000 new cases of ovarian cancer are diagnosed globally each year, with about 60% of women dying within five years after diagnosis. A clinical trial has shown testing for a specific immune biomarker could improve diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2020 Category: Cancer & Oncology Source Type: news

2 Industry Veterans Join TrialScope Connect ™ Advisory Board
TrialScope announces the appointment of Craig Lipset and Scott Ballenger to the TrialScope Connect advisory board. TrialScope Connect is an online clinical trial recruitment collective designed to...(PRWeb February 17, 2020)Read the full story at https://www.prweb.com/releases/2_industry_veterans_join_trialscope_connect_advisory_board/prweb16908089.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 17, 2020 Category: Pharmaceuticals Source Type: news

Group ("Project Life Force") versus individual suicide safety planning: a randomized clinical trial - Goodman M, Brown GK, Galfalvy HC, Spears AP, Sullivan SR, Kapil-Pair KN, Jager-Hyman S, Dixon L, Thase ME, Stanley B.
One in five suicide deaths is a Veteran and in spite of enhanced suicide prevention services in the Veterans Health Administration (VHA), twenty Veterans die by suicide each day. One component of the VHA's coordinated effort to treat high-risk suicidal Vet... (Source: SafetyLit)
Source: SafetyLit - February 15, 2020 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news

FDA Requests Market Withdrawal of Belviq Due to Cancer Risk
FRIDAY, Feb. 14, 2020 -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk for cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2020 Category: Pharmaceuticals Source Type: news

Diet Drug Belviq Withdrawn Due to Cancer Risk
The FDA asked the maker of weight-loss drug Belviq (lorcaserin) to take it off the market after a clinical trial showed an association with an increased risk of cancer. (Source: WebMD Health)
Source: WebMD Health - February 14, 2020 Category: Consumer Health News Source Type: news

Drugmaker Eisai to withdraw weight loss drug Belviq after trials find cancer link
Eisai Co. will withdraw its weight loss drug Belviq after the US Food and Drug Administration said clinical trials showed an increased incidence of cancer among users, the company said. (Source: CNN.com - Health)
Source: CNN.com - Health - February 14, 2020 Category: Consumer Health News Source Type: news

Recommendations for Under-Representation of African Americans in Multiple Myeloma
In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA In Brief: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer
FDA is requesting drug manufacturer Eisai Inc. to voluntarily withdraw its weight loss medication Belviq and Belviq XR (lorcaserin) from the U.S. market after a data analysis from a postmarket clinical trial showed that an increased occurrence of cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug
FDA has requested that the manufacturer voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai Inc,. has submitted a request to voluntarily withdraw the drug. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
FDA has requested that the weight-loss drug Belviq, Belviq XR be withdrawn from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. Stop taking the drug and talk to your health care professional if you have questions. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk
THURSDAY, Feb. 13, 2020 -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 13, 2020 Category: General Medicine Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
In this study at UCLA, a national leader in the care of patients with sarcoma, researchers used a condensed five-day radiation regimen that considerably cuts down the length of treatment and the time to surgery.“Shortening the radiation therapy from five weeks to five days has been a very meaningful change for patients,” said lead author Dr. Anusha Kalbasi, assistant professor of radiation oncology in the division of molecular and cellular oncology. “Five weeks of daily treatments is a burdensome com mitment for patients. The daily back-and-forth can be expensive and time consuming, and it can really inte...
Source: UCLA Newsroom: Health Sciences - February 13, 2020 Category: Universities & Medical Training Source Type: news

Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial
RCT (n=352) found no significant difference in the primary composite end point of mortality, persistent bacteremia, relapse, or treatment failure for addition of an antistaphylococcal β-lactam to standard antibiotic therapy (vancomycin or daptomycin) vs standard therapy alone. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 13, 2020 Category: Consumer Health News Source Type: news

R & D Focus: New report shows nearly 600 medicines in development for pediatric patients
America ’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and adolescents can be complex and often require different clinical approaches than adult treatment pathways. Acc ording to anew reportreleased today, there are nearly 600 pediatric medicines currently in development. (Source: The Catalyst)
Source: The Catalyst - February 13, 2020 Category: Pharmaceuticals Tags: Research and Development Drug Development Clinical Trials New Era of Medicine & D Focus Pediatrics Source Type: news

Changes to MRC Senior Fellowships
MRC’s mission is to improve human health through world-class medical research, from fundamental science to early clinical trials and preventive medicine. To achieve this, we are committed to attracting and developing outstanding researchers. Investing in people is one of the foundations of our 2019 strategic delivery plan. (Source: Medical Research Council General News)
Source: Medical Research Council General News - February 12, 2020 Category: Research Source Type: news

UN health agency developing COVID-19 virus treatment master plan
The World Health Organization (WHO) is developing a master plan for coordinating clinical trials that could lead to potential therapies for patients infected with the COVID-19 virus, the agency’s chief, Tedros Adhanom Ghebreyesus, announced on Wednesday. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - February 12, 2020 Category: International Medicine & Public Health Source Type: news

A Chinese Drugmaker Has Started Mass-Producing an Experimental Drug for COVID-19
A Chinese drugmaker said it has started mass-producing an experimental drug from Gilead Sciences that has the potential to fight the novel coronavirus, as China accelerates its effort to find a treatment for the widening outbreak. Suzhou-based BrightGene Bio-Medical Technology said in a statement filed to the Shanghai Stock Exchange on Tuesday night that it has developed the technology to synthesize the active pharmaceutical ingredients of remdesivir, Gilead’s drug that is a leading candidate to treat the highly-infectious virus that’s killed more than 1,000 people. The drug isn’t licensed or approved any...
Source: TIME: Health - February 12, 2020 Category: Consumer Health News Authors: Bloomberg Tags: Uncategorized Bloomberg China COVID-19 onetime overnight Source Type: news

An Alzheimer ’s Treatment Fails: ‘We Don’t Have Anything Now’
With high hopes, drugs to fight brain plaques were tested in people genetically destined to develop dementia. The drugs failed. (Source: NYT Health)
Source: NYT Health - February 11, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Alzheimer ' s Disease Elderly Drugs (Pharmaceuticals) Brain Clinical Trials Dominantly Inherited Alzheimer Network (DIAN) Eli Lilly and Company National Institute on Aging Roche Holding AG Washington University Source Type: news